GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PPD Inc (NAS:PPD) » Definitions » Altman Z-Score

PPD (PPD) Altman Z-Score : 2.18 (As of May. 11, 2024)


View and export this data going back to 2020. Start your Free Trial

What is PPD Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 2.18 is in grey area. The implies that the company is in some kind of financial stress. If it is below 1.8, the company may faces bankrupcy risk.

PPD has a Altman Z-Score of 2.18, indicating it is in Grey Zones. This implies that PPD is in some kind of financial stress. If it is below 1.81, the company may face bankrupcy risk.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for PPD's Altman Z-Score or its related term are showing as below:

PPD' s Altman Z-Score Range Over the Past 10 Years
Min: 0.93   Med: 1.52   Max: 2.18
Current: 2.18

During the past 5 years, PPD's highest Altman Z-Score was 2.18. The lowest was 0.93. And the median was 1.52.


PPD Altman Z-Score Historical Data

The historical data trend for PPD's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PPD Altman Z-Score Chart

PPD Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20
Altman Z-Score
- - - - 1.52

PPD Quarterly Data
Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.51 1.52 1.73 2.03 2.16

Competitive Comparison of PPD's Altman Z-Score

For the Drug Manufacturers - Specialty & Generic subindustry, PPD's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PPD's Altman Z-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, PPD's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where PPD's Altman Z-Score falls into.



PPD Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

PPD's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.0897+1.4*-0.2825+3.3*0.0881+0.6*2.2293+1.0*0.8365
=2.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2021:
Total Assets was $7,028 Mil.
Total Current Assets was $3,429 Mil.
Total Current Liabilities was $2,799 Mil.
Retained Earnings was $-1,986 Mil.
Pre-Tax Income was 181.858 + 79.848 + 65.142 + 103.087 = $430 Mil.
Interest Expense was -46.612 + -46.134 + -47.677 + -48.941 = $-189 Mil.
Revenue was 1560.796 + 1575.472 + 1378.38 + 1364.292 = $5,879 Mil.
Market Cap (Today) was $16,614 Mil.
Total Liabilities was $7,452 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(3429.067 - 2798.561)/7028.017
=0.0897

X2=Retained Earnings/Total Assets
=-1985.659/7028.017
=-0.2825

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(429.935 - -189.364)/7028.017
=0.0881

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=16613.934/7452.438
=2.2293

X5=Revenue/Total Assets
=5878.94/7028.017
=0.8365

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

PPD has a Altman Z-Score of 2.18 indicating it is in Grey Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


PPD  (NAS:PPD) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


PPD Altman Z-Score Related Terms

Thank you for viewing the detailed overview of PPD's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


PPD (PPD) Business Description

Traded in Other Exchanges
N/A
Address
929 North Front Street, Wilmington, NC, USA, 28401
PPD is a global contract research organization that provides clinical trial and laboratory services to pharmaceutical, device, and diagnostic firms. The clinical development services segment offers outsourced trial services, spanning early- and late-stage trials, as well as peri- and post-approval trials, and the laboratory services segment includes both advanced lab testing and central lab services. The company was taken private in 2011 and went public again in 2020.. Thermo Fisher Scientific announced it will acquire PPD for $17.4 billion, which is scheduled to close by the end of 2021.
Executives
H&f Corporate Investors Viii, Ltd. 10 percent owner 415 MISSION STREET, SUITE 5700, SAN FRANCISCO CA 94105
H&f Corporate Investors Vii, Ltd. 10 percent owner 415 MISSION STREET, SUITE 5700, SAN FRANCISCO CA 94105
David Michael Johnston officer: See Remarks C/O PPD, INC. 929 NORTH FRONT STREET WILMINGTON NC 28401
David S Simmons director, officer: Chief Executive Officer PFIZER INC. ATTN. CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Glen Donovan officer: Chief Accounting Officer C/O PPD, INC. 929 NORTH FRONT STREET WILMINGTON NC 28401
Ronald E Garrow officer: See Remarks 2000 PURCHASE STREET, PURCHASE NY 10577
Karen Kaucic officer: See Remarks C/O PPD, INC. 929 NORTH FRONT STREET WILMINGTON NC 28401
Judd Hartman officer: See Remarks 3124 DEVER COURT WILMINGTON NC 28411
Jill Pellegrino officer: SVP & General Manager of AES C/O PPD, INC. 929 NORTH FRONT STREET WILMINGTON NC 28401
H&f Executives Vii, L.p. 10 percent owner ONE MARITIME PLAZA 12TH FLOOR SAN FRANCISCO CA 94111
Hellman & Friedman Investors Viii, L.p. 10 percent owner 415 MISSION STREET, SUITE 5700, SAN FRANCISCO CA 94105
P. Hunter Philbrick director C/O HELLMAN & FRIEDMAN INVESTORS, ONE MARTIME PLAZA, 12TH FLOOR, SAN FRANCISCO CA 94111
Carlyle Partners Vi Holdings Ii, L.p. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH 1001 PENNSYLVANIA AVENUE, N.W. WASHINGTON DC 20004
Tc Group Vi, L.l.c. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA ANVENE, N.W., WASHINGTON DC 20004
Tc Group Vi, L.p. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004

PPD (PPD) Headlines

From GuruFocus

PPD Named 'Best Vaccine CRO of the Year' in Asia-Pacific

By Business Wire Business Wire 12-02-2021

Ppd Inc (PPD) CEO David S Simmons Sold $871,530 of Shares

By GuruFocus Research GuruFocus Editor 03-18-2021

PPD Wins Multiple Awards at Clinical Researcher of the Year Competition

By Business Wire Business Wire 11-22-2021

PPD to Present at Barclays Global Healthcare Conference

By Business Wire Business Wire 02-24-2021

PPD Announces Second Quarter 2021 Earnings Conference Call

By Business Wire Business Wire 07-12-2021

PPD Opens Multipurpose Clinical Research Laboratory in Suzhou, China

By Business Wire Business Wire 05-24-2021

PPD Receives Award Recognizing Employee Talent Development

By Business Wire Business Wire 09-01-2021